Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A method for identifying an agent for treating a diabetic or pre-diabetic individual, the method comprising the steps of:

(i) contacting an agent to a mixture comprising a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a nucleic acid encoding SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6~~, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12 or SEQ ID NO:14~~; and

(ii) selecting an agent that modulates the expression or activity of the polypeptide or that binds to the polypeptide, thereby identifying an agent for treating a diabetic or pre-diabetic individual.

2. (original) The method of claim 1, the method further comprising selecting an agent that modulates insulin sensitivity.

3. (original) The method of claim 1, wherein step (ii) comprises selecting an agent that modulates expression of the polypeptide.

4. (original) The method of claim 1, wherein step (ii) comprises selecting an agent that modulates the activity of the polypeptide.

5. (original) The method of claim 1, wherein step (ii) comprises selecting an agent that specifically binds to the polypeptide.

6. (original) The method of claim 1, wherein the polypeptide is expressed in a cell and the cell is contacted with the agent.

7.-16 (cancelled)

17. (currently amended) A method of diagnosing an individual who has Type 2 diabetes or is prediabetic, the method comprising,

detecting in a sample from the individual the level of a polypeptide or the level of a polynucleotide encoding the polypeptide, wherein the polynucleotide hybridizes under stringent conditions to a nucleic acid encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6~~, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12 or SEQ ID NO:14~~,

wherein a modulated level of the polypeptide or polynucleotide in the sample compared to a level of the polypeptide or polynucleotide in either a lean individual or a previous sample from the individual indicates that the individual is diabetic or prediabetic.

18. (original) The method of claim 17, wherein the detecting step comprises contacting the sample with an antibody that specifically binds to the polypeptide.

19. (original) The method of claim 17, wherein the detecting step comprises quantifying mRNA encoding the polypeptide.

20. The method of claim 19, wherein the mRNA is reverse transcribed and amplified in a polymerase chain reaction.

21. The method of claim 17, wherein the sample is a blood, urine or tissue sample.

22.-26. (cancelled)